Odonate Therapeutics announced that tesetaxel, together with a reduced dose of capecitabine, improved progression-free survival in metastatic breast cancer patients taking part in a Phase 3 clinical trial. Median progression-free survival (PFS) — the time lived until disease progression or death due to any cause — improved by 2.9 months on the combined therapy regimen as compared to capecitabine alone, rising to 9.8 months from 6.9 months. The risk of disease progression or death fell by 28.4%…
You must be logged in to read/download the full post.
The post Tesetaxel With Reduced-dose Capecitabine Improved Progression-free Survival in Metastatic Breast Cancer appeared first on BioNewsFeeds.